Novartis Sticks With Heart Of Pipeline: Growth Is In Cardio-Metabolic Sector

Novartis will continue to focus on the cardiovascular-metabolic segment in the near term with filings planned for new diabetes and hypertension therapies and line-extensions for its existing agents